$PHAT News

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals Completes Patient Enrollment In Its Phase 2 pHalcon-EoE-201 Clinical Study Of VOQUEZNA Tablets To Treat Eosinophilic Esophagitis In Adults

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Phathom: Why I'm Downgrading To "Sell" Ahead Of Competition

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline

How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

Phathom Pharmaceuticals Q1 Earnings Call Highlights

Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Phathom Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Phathom (PHAT) Q1 2026 Earnings Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (NASDAQ:PHAT) Smashes Q1 Expectations, Nears Profitability Milestone

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript

Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $320.000M-$345.000M vs $331.417M Est